Figure 3From: A randomized trial to assess the biological activity of short-term (pre-surgical) fulvestrant 500 mg plus anastrozole versus fulvestrant 500 mg alone or anastrozole alone on primary breast cancerScatter plots of individual pre- versus post-treatment data. (a) ER, (b) PgR and (c) Ki67. ER, estrogen receptor; PgR, progesterone receptor.Back to article page